Cerdulatinib

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]

Cerdulatinib
Clinical data
Other namesPRT062070, PRT2070, DMVT-502
Routes of
administration
By mouth
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC20H27N7O3S
Molar mass445.54 g·mol−1
3D model (JSmol)

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]

See also

References

  1. Liu D, Mamorska-Dyga A (July 2017). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi:10.1186/s13045-017-0512-1. PMC 5534090. PMID 28754125.
  2. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. (December 2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–48. doi:10.1124/jpet.114.218164. PMID 25253883.
  3. "Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.